CoChat

Topical Application of 5-Aminolevulinic Acid and its Methylester, Hexylester and Octylester Derivatives: Considerations for Dosimetry in Mouse Skin Model¶

Juzeniene, Asta, Juzenas, Petras, Iani, Vladimir, Moan, Johan · 2007 · Photochemistry and Photobiology
Cited by 79

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Ester derivatives of 5-aminolevulinic acid (ALA-esters) have been proposed as alternative drugs for ALA in photodynamic therapy. After topical application of creams containing ALA, ALA methylester (ALA-Me), ALA hexylester (ALA-Hex) and ALA octylester (ALA-Oct) on mouse skin, typical fluorescence excitation and emission spectra of protoporphyrin IX (PpIX) were recorded, exhibiting a similar spectral shape for all the drugs in the range of concentrations (0.5-20%) studied. The accumulation kinetics of PpIX followed nearly a similar profile for all the drug formulations. The fluorescence of PpIX peaked at around 6-12 h of continuous cream application. Nevertheless, some differences in pharmacokinetics were noticed. For ALA cream, the highest PpIX fluorescence was achieved using 20% of ALA in an ointment. Conversely, 10% of ALA-Me and ALA-Hex, but not of ALA-Oct, in the cream was more efficient (P < 0.05) than was 20%. The cream becomes rather fluid when 20% of any of these ALA-esters is used in ointment, whereas 10% and lower concentrations of ALA-esters do not significantly increase fluidity of the cream. The dependence of PpIX accumulation on the concentration of ALA and ALA-ester in the applied cream followed (P < 0.002) kinetics as described by a mathematical model based on the Michaelis-Menten equation for enzymatic processes. Under the present conditions, the PpIX amount in the skin increased by around 50% by the application of ALA-Me, ALA-Hex or ALA-Oct for 4-12 h as compared with ALA for the same period. Observations of the mice under exposure to blue light showed that after 8-24 h of continuous application of ALA, the whole mouse was fluorescent, whereas in the case of ALA-Me, ALA-Hex and ALA-Oct the fluorescence of PpIX was located only at the area of initial cream application. The amount of the active compound in the applied cream necessary to induce 90% of the maximal amount of PpIX was determined for normal mouse skin. Optimal PpIX fluorescence can be attained using around 5% ALA, 10% ALA-Me and 5% ALA-Hex creams during short application times (2-4 h). Topical application of ALA-Oct may not gain optimal PpIX accumulation for short applications (<5 h). For long application times (8-12 h), it seems that around 1% ALA, 4% ALA-Me, 6% ALA-Hex and 16% ALA-Oct can give optimal PpIX fluorescence. But for long application times and high concentrations, systemic effect of ALA applied topically on relatively large areas should be considered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1562/0031-8655(2002)0760329taoaaa2.0.co2

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 31

  1. Kalka, 2000, Photodynamic therapy in dermatology, J. Am. Acad. Dermatol, 42, 389, 10.1016/S0190-9622(00)90209-3 · DOI · Paper page
  2. Lipson, 1967, Hematoporphyrin derivative for detection and management of cancer, Cancer, 20, 2255, 10.1002/1097-0142(196712)20:12<2255::AID-CNCR2820201229>3.0.CO;2-U · DOI · Paper page
  3. Dougherty, 1990, Cutaneous phototoxic occurrences in patients receiving photofrin, Lasers Surg. Med, 10, 485, 10.1002/lsm.1900100514 · DOI · Paper page
  4. Kennedy, 1992, Clearance times of porphyrin derivatives from mice as measured by in vivo fluorescence spectroscopy, Photochem. Photobiol, 55, 729, 10.1111/j.1751-1097.1992.tb08517.x · DOI
  5. Lamola, 1982, Fluorescence studies of protoporphyrin. Transport and clearance, Acta Dermato-Venereol. Suppl. (Stockh.), 100, 57
  6. Malik, 1987, Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins, Br. J. Cancer, 56, 589, 10.1038/bjc.1987.246 · DOI · Paper page
  7. Charlesworth, 1993, The use of 5-aminolevulinic acid (ALA) in photodynamic therapy (PDT), J. Photochem. Photobiol. B: Biol, 18, 99, 10.1016/1011-1344(93)80048-E · DOI
  8. Kennedy, 1996, Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results, J. Clin. Laser Med. Surg, 14, 289, 10.1089/clm.1996.14.289 · DOI · Paper page
  9. Peng, 1997, 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges, Cancer, 79, 2282, 10.1002/(SICI)1097-0142(19970615)79:12<2282::AID-CNCR2>3.0.CO;2-O · doi:10.1002/(sici)1097-0142(19970615)79:12<2282::aid-cncr2>3.0.co;2-o
  10. Cairnduff, 1994, Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer, Br. J. Cancer, 69, 605, 10.1038/bjc.1994.112 · DOI · Paper page
  11. Szeimies, 1996, Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study, Dermatology, 192, 246, 10.1159/000246376 · DOI · Paper page
  12. Hurlimann, 1998, Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion, Dermatology, 197, 248, 10.1159/000018006 · DOI · Paper page
  13. Hongcharu, 2000, Topical ALA-photodynamic therapy for the treatment of acne vulgaris, J. Investig. Dermatol, 115, 183, 10.1046/j.1523-1747.2000.00046.x · DOI · Paper page
  14. Wolf, 1993, Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas, J. Am. Acad. Dermatol, 28, 17, 10.1016/0190-9622(93)70002-B · DOI · Paper page
  15. Svaasand, 1996, Dosimetry model for photodynamic therapy with topically administered photosensitizers, Lasers Surg. Med, 18, 139, 10.1002/(SICI)1096-9101(1996)18:2<139::AID-LSM3>3.0.CO;2-T · doi:10.1002/(sici)1096-9101(1996)18:2<139::aid-lsm3>3.0.co;2-t
  16. Kloek, 1998, Derivatives of 5-aminolevulinic acid for photodynamic therapy: enzymatic conversion into protoporphyrin, Photochem. Photobiol, 67, 150, 10.1111/j.1751-1097.1998.tb05178.x · DOI · Paper page
  17. Svaasand, 1996, Light and drug distribution with topically administered photosensitizers, Lasers Med. Sci, 11, 261, 10.1007/BF02134917 · DOI
  18. Gaullier, 1997, Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture, Cancer Res, 57, 1481
  19. Kloek, 1996, Prodrugs of 5-aminolevulinic acid for photodynamic therapy, Photochem. Photobiol, 64, 994, 10.1111/j.1751-1097.1996.tb01868.x · DOI · Paper page
  20. Lange, 1999, Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study, Br. J. Cancer, 80, 185, 10.1038/sj.bjc.6690338 · DOI · Paper page
  21. Akker, 2000, Protoporphyrin IX fluorescence kinetics and localization after topical application of ALA pentyl ester and ALA on hairless mouse skin with UVB-induced early skin cancer, Photochem. Photobiol, 72, 399, 10.1562/0031-8655(2000)072<0399:PIFKAL>2.0.CO;2 · doi:10.1562/0031-8655(2000)072<0399:pifkal>2.0.co;2
  22. Shanley, 1975, Neurochemical aspects of porphyria. Studies on the possible neurotoxicity of δ-aminolaevulinic acid, S. Afr. Med. J, 49, 576
  23. Emanuelli, 2001, Inhibition of adenylate cyclase activity by 5-aminolevulinic acid in rat and human brain, Neurochem. Int, 38, 213, 10.1016/S0197-0186(00)00092-9 · DOI
  24. Pottier, 1986, Non-invasive technique for obtaining fluorescence excitation and emission spectra in vivo, Photochem. Photobiol, 44, 679, 10.1111/j.1751-1097.1986.tb04726.x · DOI · Paper page
  25. Johansson, 1997, Laser-induced fluorescence studies of normal and malignant tumour tissue of rat following intravenous injection of δ-amino levulinic acid, Lasers Surg. Med, 20, 272, 10.1002/(SICI)1096-9101(1997)20:3<272::AID-LSM6>3.0.CO;2-N · DOI
  26. Gerscher, 2000, Comparison of the pharmacokinetics and phototoxicity of protoporphyrin IX metabolized from 5-aminolevulinic acid and two derivatives in human skin in vivo, Photochem. Photobiol, 72, 569, 10.1562/0031-8655(2000)072<0569:COTPAP>2.0.CO;2 · doi:10.1562/0031-8655(2000)072<0569:cotpap>2.0.co;2
  27. Sorensen, 1999, Photochemotherapy of Cancer and Other Diseases., 3563, 77, 10.1117/12.339121 · DOI
  28. Casas, 1999, Comparative effect of ALA derivatives on protoporphyrin IX production in human and rat skin organ cultures, Br. J. Cancer, 80, 1525, 10.1038/sj.bjc.6690556 · DOI · Paper page
  29. Juzeniene, 2002, The temperature effect on the accumulation of protoporphyrin IX after topical application of 5-aminolevulinic acid and its methylester and hexylester derivatives in normal mouse skin, Photochem. Photobiol.
  30. Juzenas, 1999, Photochemotherapy of Cancer and Other Diseases, 3563, 161, 10.1117/12.339134 · DOI
  31. Moan, 2001, On the pharmacokinetics of topically applied 5-aminolevulinic acid and two of its esters, Int. J. Cancer, 92, 139, 10.1002/1097-0215(200102)9999:9999<::AID-IJC1154>3.0.CO;2-K · DOI · Paper page

Cited by

See all 79

Metadata

Authors
Juzeniene, A., Juzenas, P., Iani, V., & Moan, J.
Venue
Photochemistry and Photobiology
Published
2007-05-01
Volume
76
Issue
3
Pages
329-334
ISSN
0031-8655 (ISSN-L)
OpenAlex
W1966580456
Cited by
79
References
6
FWCI
3.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Topical Application of 5-Aminolevulinic Acid and its Methylester, Hexylester and Octylester Derivatives: Considerations for Dosimetry in Mouse Skin Model¶. https://app.cochat.ai/papers/10.1562/0031-8655(2002)0760329taoaaa2.0.co2
The paper
Juzeniene, A., Juzenas, P., Iani, V., & Moan, J. (2007). Topical Application of 5-Aminolevulinic Acid and its Methylester, Hexylester and Octylester Derivatives: Considerations for Dosimetry in Mouse Skin Model¶. Photochemistry and Photobiology. https://doi.org/10.1562/0031-8655(2002)0760329taoaaa2.0.co2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.